Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735.

Northfelt, Donald W.; Dueck, A. C.; Flynn, Thomas P.; Zander, P. J.; Stella, Philip J.; Melnik, Marianne K.; Pavey, EmilyS S; Perez, Edith A.

doi:10.1200/jco.2011.29.15_suppl.1126

Cited by 8 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the primary endpoint PFS was 39.7 weeks, a result which is consistent with two similar studies that showed PFS of 41.7 weeks [29] and 47.9 weeks [30]. The trial performed by Northfelt et al met its prespecified endpoint of 6 months PFS > 60% and its toxicities were manageable [23]. The trial performed by Halmilton showed PFS of 9.2 months in comparison to a similar study with PFS of 6.1 months [37,38], and also described a favorable rate of febrile neutropenia (3%) and neuropathy (6% grade 3, no grade 4) in comparison to historical control treatments [24].…”

Section: Discussionsupporting

confidence: 74%

“…The most common adverse effects were neutropenia, fatigue, thrombocytopenia, anemia, leukopenia, and dyspnea. This regimen should be further evaluated in regimens of chemotherapy plus targeted agents in metastatic breast cancer [23]. Another phase II study was performed by Hamilton et al to evaluate the efficacy of treatment with abraxane plus carboplatin plus bevacizumab in 41 women with TNMBC.…”

Section: Nanoparticle Albumin-stabilized Paclitaxelmentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

et al. 2021

View full text Add to dashboard Cite

Breast cancer was responsible for the deaths of 626,679 women in 2018. After decades of research, the mortality rates remain high. While the barrier of selectively killing tumor cells is not yet overcome, the search for targeted therapeutics continues. The use of nanomedicine in cancer treatment has opened up new possibilities for more precise drug-delivery systems. This review aimed to gather information and analyze recent clinical trials evaluating the therapeutic effects of nanoparticles in the treatment of metastatic breast cancer. To accomplish this, the clinicaltrials.gov database was consulted, and after employing specific exclusion criteria, 11 clinical trials were selected. Nanoparticle albumin-stabilized paclitaxel was evaluated in ten clinical trials and paclitaxel-incorporating polymeric micelles were assessed in one clinical trial. Overall, this review confirmed a clinical benefit in the use of nanoparticle albumin-stabilized paclitaxel for the treatment of breast cancer, with reduced toxicity when compared to first-line treatments. Three studies did not meet the primary endpoint, however, and so the authors advised further evaluations. Although the use of nanomedicine is revolutionizing the cancer field, to integrate this regimen into generalized clinical treatment, additional clinical trials must be performed to achieve a favorable safety and efficacy profile.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Nanoparticle Albumin-stabilized Paclitaxelmentioning

confidence: 99%

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The most common grade 3/4 adverse event was neutropenia with 71%. Neuropathy grade 3 occurred in 4 (8%) patients [20].…”

Section: Weekly Administration Of Nab-paclitaxel As Single Agent In Mbcmentioning

confidence: 99%

“…Nab-paclitaxel combinations at a dose of 125 mg/m 2 with capecitabine and gemcitabine were feasible, safe and active [15,16]. Triple combinations of a biological and 2 cytotoxic agents as first-line treatment were tested with the 125 mg/m 2 dose plus gemcitabine and the 100 mg/m 2 dose with carboplatin, and proved active and manageable [19,20,22]. For most physicians involved in the care of patients with pretreated MBC, a weekly schedule of nab-paclitaxel might be the preferred choice because it allows them to monitor treatment closely and to react promptly to the onset of side effects such as neuropathy.…”

Section: Weekly Administration Of Nab-paclitaxel As Single Agent In Mbcmentioning

confidence: 99%

Weeklynab-Paclitaxel in Metastatic Breast Cancer Summary and Results of an Expert Panel Discussion

Jackisch

Lück²,

Untch³

et al. 2012

Breast Care

View full text Add to dashboard Cite

Taxanes are regarded as the most effective single agents in the treatment of metastatic breast cancer (MBC). For conventional taxanes, crucial toxicities and impairments in clinical efficacy are related to solvents necessary because of the agents’ hydrophobicity. The mandatory premedication with corticosteroids causes additional side effects. Nab-paclitaxel is a solvent-free colloidal suspension of paclitaxel and human serum albumin that exploits the physiological transport properties of albumin. It is registered as monotherapy with a recommended dose of 260 mg/m² every 3 weeks for the treatment of patients with MBC, who have failed a first-line treatment of metastatic disease and for whom a standard anthracycline treatment is not indicated. Clinical evidence is available for the registered 3-weekly administration and for alternative weekly schedules in first and further lines of therapy of patients with MBC. During an advisory board meeting, a group of 8 German breast cancer experts reviewed the clinical data of nab-paclitaxel in MBC and discussed how nab-paclitaxel could be used in clinical practice on the basis of the current data.

show abstract

“…The following supporting information can be downloaded at: , Table S1: the current nanopharmaceuticals for cancer therapy in clinical assays [ 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 ].…”

mentioning

confidence: 99%

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges

Rodríguez

Caruana

Fuente³

et al. 2022

Biomolecules

112

View full text Add to dashboard Cite

Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe undesirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.

show abstract

Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735.

Cited by 8 publications

References 0 publications

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

Weeklynab-Paclitaxel in Metastatic Breast Cancer Summary and Results of an Expert Panel Discussion

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges

Contact Info

Product

Resources

About

Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735.

Cited by 8 publications

References 0 publications

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

Weeklynab-Paclitaxel in Metastatic Breast Cancer  Summary and Results of an Expert Panel Discussion

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges

Contact Info

Product

Resources

About

Weeklynab-Paclitaxel in Metastatic Breast Cancer Summary and Results of an Expert Panel Discussion